FY2027 Q2 (interim) results. Revenue was 76,871 million yen, cost of sales was 36,879 million yen, and gross profit was 39,991 million yen. Selling, general and administrative expenses were 40,891 million yen, and research and development expenses were 20,585 million yen. Operating income was -899 million yen (worsened YoY), ordinary income was -206 million yen, and net income attributable to owners of parent was 2,144 million yen. Overseas sales were 13,102 million yen, with nine months of contribution from the Aadi acquisition. Comparisons with planned figures are also provided.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4521","jir_company_name":"Kaken Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4521-20261109-02.pdf","jir_short_summary":"FY2027 Q2 (interim) results. Revenue was 76,871 million yen, cost of sales was 36,879 million yen, and gross profit was 39,991 million yen. Selling, general and administrative expenses were 40,891 million yen, and research and development expenses were 20,585 million yen. Operating income was -899 million yen (worsened YoY), ordinary income was -206 million yen, and net income attributable to owners of parent was 2,144 million yen. Overseas sales were 13,102 million yen, with nine months of contribution from the Aadi acquisition. Comparisons with planned figures are also provided.","jir_summary":"### Key Points of Performance\nOn a consolidated basis for FY2027 Q2, revenue was 76,871 million yen and overseas sales were 13,102 million yen, exceeding the prior-year period; however, operating income widened to a loss of -899 million yen. Ordinary income was -206 million yen, and net income attributable to owners of parent was 2,144 million yen, indicating a significant improvement in net profit. Profit and loss recognition from the acquisition of Aadi was recorded for nine months. The planned revenue for the fiscal year is 89,900 million yen.\n\n### Segments, Pipeline and Overseas Expansion\nThe Pharmaceuticals segment drives domestic and international sales. For exported products, progress has been made on domestic application of efinaconazole, and parts of the pipeline such as KP-001 are in Phase III and PK stages. The increase in overseas sales also affects the sales composition of major domestic pharmaceuticals. Profit and loss recognition related to the Aadi acquisition has an impact, so attention is required regarding transitions in financial indicators.","jir_financial_highlights":"Revenue: 76,871 (YoY +24.4% (full-year plan: 89,900))\nOperating Income: -899 (YoY - (Unknown))\nNet Income Attributable to Owners of Parent: 2,144 (YoY +698.1% (as of September 30))\nOverseas Sales: 13,102 (YoY +254.8% (plan: 30,500))","jir_category":"","jir_hashtags":"#KakenPharmaceutical, #Earnings, #IRResults","jir_key_figures":"Revenue: 76,871 million yen\nOverseas Sales: 13,102 million yen\nNet Income Attributable to Owners of Parent: 2,144 million yen","jir_meta_title":"Kaken Pharmaceutical Co., Ltd. Earnings Report Supplemental Materials | FY2027 Q2","jir_meta_description":"Summary of Kaken Pharmaceutical's FY2027 Q2 results: revenue and profit trends, overseas sales, impact of the Aadi acquisition, and outlook. Includes segment breakdown and pipeline status.","jir_og_title":"Kaken Pharmaceutical Earnings Report Supplemental Materials | FY2027 Q2","jir_og_description":"From Kaken Pharmaceutical's earnings supplemental materials: key points on revenue, profits, overseas sales, impact of the Aadi acquisition, and future plans.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2026 Q2\\\",\\\"FY2027 Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[39356,76871]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2026 Q2\\\",\\\"FY2027 Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[180,-899]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceuticals\\\",\\\"Real Estate Business\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[476? , 131?]}]},\\\"options\\\":{}}\"}]","ir_related_company":9082,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-145538","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n